Last reviewed · How we verify
raltegravir (Isentress)
Raltegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA.
Raltegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in pediatric patients.
At a glance
| Generic name | raltegravir (Isentress) |
|---|---|
| Also known as | ISENTRESS, MK-0518 |
| Sponsor | Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux |
| Drug class | Integrase strand transfer inhibitor (INSTI) |
| Target | HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks the catalytic activity of HIV integrase, the enzyme responsible for inserting viral DNA into the human genome. By preventing this integration step, the drug blocks HIV replication and reduces viral load in infected individuals. This mechanism is distinct from reverse transcriptase or protease inhibitors and represents a newer class of antiretroviral therapy.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in pediatric patients
Common side effects
- Nausea
- Diarrhea
- Headache
- Insomnia
- Elevated creatine kinase
Key clinical trials
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (PHASE4)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Pregnancy, Anti-integrase and Lymphocyte Repertoire of the Newborn
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Therapeutic Drug Monitoring to oPtimize ANtiretroviral regimeNs in HIV-infected Women Who wAnt to Breastfeed
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: